- CEO
- Abdulsalam Musfer Al Ghamdi
- Full Time Employees
- 300
- Sector
- Process industries
- Industry
- Industrial specialties
- Address
- P.O. Box 2665 Riyadh Riyadh Province Saudi Arabia 11482
- IPO Date
- May 6, 2001
- Business
- Saudi Chemical Holding Company (2230.SR), founded in 1972 and headquartered in Riyadh, Saudi Arabia, manufactures and sells explosives and related products for civil and military applications; trades medicines, medical supplies, pharmaceuticals, medical and surgical equipment, cosmetics, perfumes, and beauty products; and produces ammonium nitrate. The company operates through three main segments—Explosives, Medicine and Medical Supplies, and Ammonium Nitrate Production—with products including electronic detonators, blasting agents, initiation systems, seismic explosives, and accessories, serving domestic markets in Saudi Arabia via factories in Riyadh, Jeddah, and the Eastern Province, as well as exporting to Gulf, Arab, and other countries. Subsidiaries such as Saudi Chemical Company Ltd., Suez International Nitrate Company, Saudi International Trading Company (SITCO Pharma), AJA Pharmaceutical Industries Ltd., and Chemical Commercial Investment Company Ltd. support its diversified operations in chemicals, pharmaceuticals, and defense-related industries.
Recent developments include a December 2024 memorandum of understanding signed by subsidiary Saudi Chemical Company Limited with Dyno Nobel to establish a production facility; a partnership with the National Company for Military Industries (NCMS) in February 2024 to develop defense technologies; and a January 2024 agreement to build an ammonium nitrate and nitric acid facility in Ras Al-Khair for mining and defense applications. In December 2023, subsidiary AJA Pharmaceuticals entered a binding agreement with Dr. Reddy’s Laboratories for licensing three injection products across Saudi Arabia and GCC countries; earlier that year, it signed an MoU with Moxico Resources and Ajlan & Bros for blasting services at the Al-Khunayqiyah mine. Additional recent moves encompass executive changes, including the resignation of former CEO Thamer Mohmmed Al Muhid and appointment of Abdulsalam Musfer Al Ghamdi; board approval for subsidiary ownership restructuring; and multiple pharmaceutical MoUs with partners like Remedica, Bioventure, and Lagap for product co-development and commercialization.